BiomX, APT merger to advance CF treatment BX004 into Phase 2 trial

BiomX and Adaptive Phage Therapeutics (APT) are entering into a merger agreement with a goal of pooling resources to advance phage therapies such as BX004 — an experimental cystic fibrosis (CF) treatment that aims to clear up lung infections caused by Pseudomonas aeruginosa bacteria. At the same time as…

Proteostasis Therapeutics Merges With Yumanity Therapeutics

Proteostasis Therapeutics (PTI) has entered into a definitive merger agreement with Yumanity Therapeutics to leverage their common expertise about protein misfolding to advance the development of disease-modifying therapies for several disorders. The merger should be complete before the end of the year. The combined company will operate under the…